



1









## 4 Requirements for Successful MRS

- 1. Incredibly homogeneous magnetic field
- 2. Effective water/fat suppression
- 3. High-quality localization
- 4. Robust analysis

### Magnetic Field Homogeneity

- MRI requires a homogeneous magnetic field. MRS requires an <u>incredibly</u> homogeneous field.
- FWHM  $\propto 1/T_2^*$  so better homogeneity  $\rightarrow$  narrower peaks (i.e. better spectral resolution).
- Narrow peaks are also required for good water suppression.
- Good shimming is critical
  - Figure out which technique works best on your scanner.
  - Repeat the shim and/or re-position the patient if necessary.
  - Use a system with at least 2<sup>nd</sup>-order shims.











- For a spectrum to aid clinical diagnosis, the location from which it was obtained must be known accurately.
- Surface coil localization was originally used for superficial lesions and cardiac studies, but is no longer common.
- Single voxel spectroscopy (SVS) and multi-voxel spectroscopy (MVS, a.k.a. spectroscopic imaging [SI]) are currently used in the clinic.











### semi-LASER

Mitigates most of the problems with LASER, while keeping most of the benefits of using adiabatic pulses.

# Sequence Recommendation

#### For routine clinical use:

- 1. Try semi-LASER if you have it.
- 2. If not available, try PRESS (3 T and lower) or STEAM (7 T).

Wilson, Martin, et al. "Methodological consensus on clinical proton MRS of the brain: Review and recommendations." Magnetic resonance in medicine 82.2 (2019): 527-550.





# **MRS** Analysis

- Goal is to quantify different metabolites and several software packages are available.
- Spectra are processed (baseline correction, phase correction, apodization, Fourier transform, etc.) and then quantified.
- Some software programs are significantly more advanced than others.

# MRS Analysis Software

#### **Vendor Basic**

Comes with the vendor MRS package.

#### Often automatic.

Very simple peak height or integral quantification.

Only a few metabolites can be quantified.

#### **Vendor Agnostic**

e.g. LCModel, Tarquin

Very advanced software with sophisticated fitting algorithms.

Fully customizable (basis sets, metabolites, processing, etc.).

Provide estimates of quantification errors and metrics of spectral quality.

Not FDA approved.

#### **Vendor Advanced**

e.g. Syngo, IntelliSpace, READYView

Best of both worlds.

Rapidly approaching vendor agnostic software in terms advanced features.

Allows for sophisticated processing, custom metabolites, error estimation, etc.









# Signal Bleed

- Typically evidenced by the phase difference and broadness of the peak.
- This particular voxel was located very near the skull and sequence/pulse imperfections (and, possibly, patient motion) acquired some signal from the scalp.
- OVS is important.



C	NS
<ul> <li>MRS is indicated for a variety of neurological conditions</li> </ul>	Performance and Interpretation of Magnetic Resonance Spectroscopy of the Central Nervous System (2019).
• The most common uses include:	When conventional imaging by magnetic resonance imaging (MRI) or computed tomography (CT) provides limited information regarding specific clinical questions, indications for MRS in adults and children include, but are not limited to , the following:
<ul> <li>Primary diagnosis of brain lesions.</li> </ul>	<ol> <li>Evidence or suspicion of primary or secondary neoplasm (pretreatment and posttreatment)</li> <li>Grading of primary glial neoplasm, particularly high-grade versus low-grade glioma [5.6]</li> <li>Evidence or suspicion of brain infections especially cerebral abscess (pretreatment and posttreatment) and HIV-related infections</li> <li>Seizures, especially temporal lobe epilepsy</li> <li>Evidence or suspicion of neurodegementive disease, especially Alzheimer's disease, Parkinson's disease, and Hutington's disease [7-9]</li> </ol>
<ul> <li>Distinguishing recurrent brain tumor from radiation necrosis.</li> </ul>	<ol> <li>Evidence or suspicion of subclinical or clinical hepatic encophalopathy</li> <li>Evidence or suspicion of an inherited metabolic disorder, such as Canavan disease, mitochondrial encophalopathies, and other leukodystrophies [10,11]</li> <li>Suspicion of acute brain ischemia or infraction, including brith asphyxia [12]</li> <li>Evidence or suspicion of a demyclination or dysmyclination disorder [13-16]</li> <li>Devidence or suspicion of brain developmental abnormality and cerebral palsy</li> <li>Evidence or suspicion of brain developmental abnormality and cerebral palsy</li> <li>Evidence or suspicion of other metrodegenerative diseases, such as anyotrophic lateral selerosis</li> </ol>
<ul> <li>Diagnosis of inborn errors of metabolism affecting the CNS.</li> </ul>	<ol> <li>Evidence or suspicion of chronic pain syndromes</li> <li>Evidence or suspicion of chronic somal and inherited neurocutaneous disorders, such as neurofibromatosis and tuberous sclerosis</li> <li>Evidence or suspicion of neurotoxicity, such as missue of medications, and exposure to environmental hazards, such as carbon monoxide and inhalants</li> <li>Evidence or suspicion of spixal exchemic encephalopathy</li> <li>Evidence or suspicion of popular cord disorders, such as tumors, demyelination, infection, and trauma (17.26)</li> <li>Differentiation between recurrent tumor and treatment-related changes or radiation injury</li> <li>Differentiation between recurrent tumor and treatment-related changes or radiation injury</li> <li>Differentiation of cystic lesions (e.g. abacess versus cystic metastasis or cystic primary neoplasm)</li> <li>Evidence or suspicion of cerebral vasculistic, systemic lunger sythematous (E.L.), and neuropsychiatric</li> <li>Evidence or suspicion of cerebral vasculistic, systemic lunger sythematous (E.L.), and neuropsychiatric</li> <li>Eviduation of response to treatment of neurological disorders (e.g. tumore evaluation)</li> <li>Eviduation of response to treatment of neurological disorders</li> <li>Dividuation of response to treatment of neurological disorders</li> </ol>

## CNS

- Primary peaks:
  - Total NAA (2.0 ppm)
    - N-acetylaspartate and Nacetylaspartylglutamate
    - Neuronal marker
  - Total Cr (3.0 ppm)
    - Creatine and phosphocreatine
    - Energy buffer
    - Total Ch (3.2 ppm)
      - Choline, glycerophosphorylcholine and phosphorylcholine
      - Membrane turnover





Courtesy of R. Jason Stafford

	CNS
<ul> <li>Other peaks:</li> <li>Glx (glutamine, glutamate)</li> <li>γ-Aminobutyric acid</li> <li>Lactate</li> <li>Lipids</li> <li>Myo- and scyllo-inositol</li> <li>Citrate</li> <li>(D)-2-hydroxyglutarate (2HG)</li> <li>Taurine</li> <li>Glucose</li> <li>Ethanol</li> <li>Mannitol</li> <li>Acetate and succinate</li> <li>Branched-chain amino acids</li> </ul>	A a b c c c d d d d d d d d d d d d d

IVINS QA
----------

AAPM Report 78 (2002) details
 recommended MRS QA based on
 a simple phantom.

- AAPM Report 100 (2010) details recommended MRS acceptance testing using a phantom.
- I personally argue that phantombased MRS QA alone is insufficient since the phantom poorly emulates both the biochemical milieu and electromagnetic environment found in vivo.
- I would argue that every spectrum from every scan from every patient be verified for quality before being sent to a radiologist.

### Reimbursement

• CPT code 76390

